Home › Diffuse Intrinsic Pontine Glioma
Diffuse Intrinsic Pontine Glioma clinical trials recruiting in the U.S.
23 studies for Diffuse Intrinsic Pontine Glioma are recruiting participants at sites across the United States.
Cities with the most studies
- Washington, DC11 studies
- Seattle, WA10 studies
- Houston, TX10 studies
- Columbus, OH10 studies
- Cincinnati, OH10 studies
- Philadelphia, PA10 studies
- Durham, NC9 studies
- Boston, MA9 studies
- Chicago, IL9 studies
- Aurora, CO8 studies
- Ann Arbor, MI6 studies
- Miami, FL6 studies
- St. Louis, MO5 studies
- Atlanta, GA4 studies
- New York City, NY3 studies
- Los Angeles, CA3 studies
- Birmingham, AL3 studies
By state
- Alabama3 studies
- California5 studies
- Colorado8 studies
- District of Columbia11 studies
- Florida7 studies
- Georgia4 studies
- Illinois9 studies
- Massachusetts9 studies
- Michigan6 studies
- Missouri5 studies
- New York3 studies
- North Carolina9 studies
- Ohio12 studies
- Pennsylvania12 studies
- Texas11 studies
- Washington10 studies
Recently updated studies
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Sep 21, 2026 · NCT06838676CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
RecruitingPhase 1
Ages 3 to 25 · All sexes · Updated Sep 9, 2026 · NCT07664176Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
RecruitingPhase 1
36 Months · All sexes · Updated Sep 9, 2026 · NCT07076498Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
RecruitingPhase 2
Ages 1 to 26 · All sexes · Updated Aug 4, 2026 · NCT07680439Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
RecruitingPhase 1
Ages 2 to 25 · All sexes · Updated Aug 3, 2026 · NCT06624371C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
RecruitingPhase 1
12 Months – 25 Years · All sexes · Updated Aug 3, 2026 · NCT04099797Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Combination Therapy for the Treatment of Diffuse Midline Gliomas
RecruitingPhase 2
Ages 2 to 39 · All sexes · Updated Jun 26, 2026 · NCT05009992Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Apr 13, 2026 · NCT04185038A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
RecruitingPhase 1
12 Months – 18 Years · All sexes · Updated Mar 17, 2026 · NCT04943848FUS Etoposide for DMG
RecruitingPhase 1
Ages 4 to 21 · All sexes · Updated Jan 28, 2026 · NCT05762419Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RecruitingPhase 1/2Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Dec 8, 2025 · NCT05956821International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
RecruitingObservational study
All ages · All sexes · Updated Oct 20, 2025 · NCT03101813Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
RecruitingObservational study
Up to age 21 · All sexes · Updated Aug 20, 2024 · NCT01106794xPedite: A Study to Expedite DIPG and DMG Research
RecruitingObservational study
All ages · All sexes · Updated Apr 30, 2024 · NCT06140719From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.